Changing gastric cancer treatment in the United States and the pursuit of quality.
The low incidence of gastric cancer in the US presents various quality challenges. For most US practitioners, individual experience is inadequate. Accrual to clinical trials testing new treatments can be daunting. However, through the use of nationally available clinical trials sponsored by many trial groups working in concert, and the use of national registries for treatment and outcome surveillance, a path to increased gastric cancer survival has been charted. Moreover, systems for continuous quality improvement at the institutional level are in place. Quality assurance is an increasing concern of both private and governmental groups. In this article, we summarize recent national US clinical trial findings concerning gastric cancer treatment, highlight national assessment systems for cancer outcomes, and describe what these systems tell us about the current status of gastric cancer care in the US, highlighting challenges and areas for potential improvement.
Hundahl
S A
SA
VA Northern California Health Care System, Sacramento VA Medical Center, University of California at Davis, Mather, CA 95655-1200, USA. scott.hundahl@med.va.gov
Wanebo
H J
HJ
D017024:Chemotherapy, Adjuvant; D002986:Clinical Trials as Topic; D006801:Humans; D010043:Outcome and Process Assessment, Health Care; D011785:Quality Assurance, Health Care; D018714:Radiotherapy, Adjuvant; D013274:Stomach Neoplasms / Q000601:surgery / Q000628:therapy*; D016896:Treatment Outcome; D014481:United States